Galmed Pharma (GLMD) Reports In-Line Q4 EPS

Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.30), in-line with the analyst estimate of ($0.30).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• The tech crown switches hands: Apple dethrones Nvidia as $4 trillion king
• South Plains Financial Inc. (SPFI) Tops Q2 EPS by 1c
• Galmed develops heart-targeted nanoparticle formulation of Aramchol